Table 3 Differences according to the presence or absence of HER2 expression in differentiated-type EGC.
From: HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
|  | Total (n = 206) | Negative (n = 177) | Positive (n = 29) | p-value |
|---|---|---|---|---|
Age | Â | Â | Â | 0.633 |
<60 | 72 (35.0%) | 63 (35.6%) | 9 (31.0%) | Â |
≥60 | 134 (65.0%) | 114 (64.4%) | 20 (69.0%) |  |
Sex | Â | Â | Â | 0.486 |
M | 168 (81.6%) | 143 (80.8%) | 25 (86.2%) | Â |
F | 38 (18.4%) | 34 (19.2%) | 4 (13.8%) | Â |
Tumour size | Â | Â | Â | 0.158 |
≤20 | 66 (32.0%) | 60 (33.9%) | 6 (20.7%) |  |
>20 | 140 (68.0%) | 117 (66.1%) | 23 (79.3%) | Â |
Vertical location | Â | Â | Â | 0.145 |
UT/MT | 102 (49.5%) | 84 (47.5%) | 18 (62.1%) | Â |
LT | 104 (50.5%) | 93 (52.5%) | 11 (37.9%) | Â |
Gross type | Â | Â | Â | 0.615 |
E | 56 (27.2%) | 47 (26.6%) | 9 (31.0%) | Â |
F/D | 150 (72.8%) | 130 (73.4%) | 20 (69.0%) | Â |
Depth of invasion | Â | Â | Â | 0.219 |
SM | 99 (48.1%) | 82 (46.3%) | 17 (58.6%) | Â |
M | 107 (51.9%) | 95 (53.7%) | 12 (41.4%) | Â |
LVI | Â | Â | Â | 0.199 |
No | 167 (81.1%) | 146 (82.5%) | 21 (72.4%) | Â |
Yes | 39 (18.9%) | 31 (17.5%) | 8 (27.6%) | Â |
Node metastasis | Â | Â | Â | >0.99 |
No | 184 (89.3%) | 158 (89.3%) | 26 (89.7%) | Â |
Yes | 22 (10.7%) | 19 (10.7%) | 3 (10.3%) | Â |
